Contact
Please use this form to send email to PR contact of this press release:
Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and Provides COVID-19 Business Update
TO: